Answers are grounded in this paper and cite their sources.
Background: HIV infection and antiretroviral therapy (ART) are associated with dyslipidaemia in children. Protease-inhibitor-based regimens, in particular, have shown the highest association. Methods: We conducted a retrospective study of children treated with either a first- or second-line lopinavir/ritonavir (LPV/r) regimen who had any non-fasting lipid tests done from 2004 to 2015. Dyslipidaemia was defined as hypercholesterolaemia (total cholesterol ≥5.13 mmol/l) and/or hypertriglyceridaemia (total triglycerides ≥1.69 mmol/l). There were four cross-sectional points of analysis in this study: ART start, LPV/r start, 12 and 24 months. Demographic and clinical characteristics were compared using univariate and multivariate analyses to determine risk factors for dyslipidaemia at each time point. Results: The median age at ART start was 1.6 (0.4; 4.4) increasing to 3.6 (2.6; 6.2) years by 24 months. The majority (51%) of the children had severe immune suppression (CD4 count <200 or CD4% < 15%) at ART start. The prevalence of dyslipidaemia at ART start was 47%, decreasing to 36% at 24 months. Multivariate analysis at 12 months found that children less than 10 years of age and despite having near suppressed/suppressed viral loads (<10,000 copies/ml) were more likely to have dyslipidaemia. Furthermore, ART duration more than 24 months was associated with less dyslipidaemia. Conclusion: The high prevalence of dyslipidaemia in young children is concerning as LPV/r is the mainstay of ART in young children for the foreseeable future.
No takes yet. Share an insight, caveat, or question.
Sipambo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: